^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Undisclosed anti-KRAS G12D mTCR PBL
i
Other names: Undisclosed anti-KRAS G12D mTCR PBL
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Gilead, National Cancer Institute - Bethesda
Drug class:
KRAS inhibitor, T lymphocyte replacement
Related drugs:
2years
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (clinicaltrials.gov)
P1/2, N=70, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
Enrollment open • Preclinical • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12
|
cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Undisclosed anti-KRAS G12D mTCR PBL
over3years
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (clinicaltrials.gov)
P1/2, N=4, Suspended, National Cancer Institute (NCI) | Active, not recruiting --> Suspended
Preclinical • Trial suspension • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12
|
fludarabine IV • Proleukin (aldesleukin) • Undisclosed anti-KRAS G12D mTCR PBL
over3years
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (clinicaltrials.gov)
P1/2, N=4, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=70 --> 4
Enrollment closed • Preclinical • Enrollment change • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12
|
fludarabine IV • Proleukin (aldesleukin) • Undisclosed anti-KRAS G12D mTCR PBL
Share via
